why choose us

First received: May 10, 2023

Clinical Trial: An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

Study Status: Completed

Recruit Status: RECRUITING

Condition: Ovary Cancer

Study Type: INTERVENTIONAL


Official Title: A Phase II Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib in Recurrent Platinum Sensitive Ovarian, Peritoneal, and Fallopian Tube Cancer

Brief Summary: The Principal Investigator hypothesizes the combination of MIRV and Olaparib is an effective, and tolerable, maintenance therapy strategy in platinum sensitive recurrent ovarian cancer.

Read more